Effect of poloxamer CRL-1072 on drug uptake and nitric-oxide-mediated killing of Mycobacterium avium by macrophages

Immunopharmacology

Volumn 48, Issue 2, 2000, Pages 185-197

  Jagannath, Chinnaswamy ^a   Sepulveda, Eliud ^a   Actor, Jeffrey K ^a   Luxem, Franz ^b   Emanuele, Martin R ^b   Hunter, Robert L ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b CytRx Corporation   (United States)

Author keywords

Drug; Mechanism; Mycobacteria; Mycobacterium avium intracellulare; Nitric oxide; U937

Indexed keywords

CRL 1072; ERYTHROMYCIN; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; POLOXAMER; STREPTOMYCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIMICROBIAL ACTIVITY; ARTICLE; CELL KILLING; CELL STRAIN U937; CONTROLLED STUDY; DRUG POTENTIATION; DRUG UPTAKE; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; MYCOBACTERIUM AVIUM; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; HUMANS; MACROPHAGES; MYCOBACTERIUM AVIUM; NITRIC OXIDE; POLOXAMER; U937 CELLS;

EID: 0034691583     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(00)00203-4     Document Type: Article

References (55)

1. Actor J.K., Kuffner T., Dezzutti C.S., Hunter R.L., McNicholl J.M. A flash-type bioluminescent immunoassay that is more sensitive than radioimaging: quantitative detection of cytokine cDNA in activated and resting human cells. J. Immunol. Methods. 211:1998;65-77.
2. Actor J.K., Limor J.R., Hunter R.L. A flexible bioluminescent-quantitative polymerase chain reaction assay for analysis of competitive PCR amplicons. J. Clin. Lab. Anal. 13:1999;40-47.
3. Bates J.H. Mycobacterium avium disease: progress at last [editorial comment]. Am. J. Respir. Crit. Care Med. 153:1996;1737-1738.
4. Behling C.A., Nolte F.S., Tinkley A., Hunter R.L. The effect of tyloxapol on the surface lipids and biologic activities of BCG. Vaccine Res. 3:1994;1-14.
5. Bermudez L., Wu M., Young L. Interleukin-12-stimulated natural killer cells can activate human macrophages to inhibit growth of Mycobacterium avium. Infect. Immun. 63:1995;4099-4104.
6. Bermudez L., Young L. Natural killer cell-dependent mycobacteriostatic and mycobactericidal activity in human macrophages. J. Immunol. 146:1991;265-270.
7. Bermudez L., Young L. Oxidative and non oxidative intracellular killing of Mycobacterium avium complex. Microb. Pathogen. 7:1989;289-298.
8. Bermudez L., Young L. Tumor necrosis factor, alone or in combination with IL-2, but not IFN-gamma, is associated with macrophage killing of Mycobacterium avium complex. J. Immunol. 140:1988;3006-3013.
9. Bermudez L.E., Stevens P., Kolonoski P., Wu M., Young L. Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. J. Immunol. 143:1989;2996-3000.
10. Blanchard D.K. Cytokine activation of killer cells in mycobacterial immunity. Adv. Exp. Med. Biol. 319:1992;105-112.
11. Blanchard D.K., Michelini-Norris M., Pearson C., McMillen S., Djeu J. Production of granulocyte-macrophage colony-stimulating factor (GM-CSF) by monocytes and large granular lymphocytes stimulated with Mycobacterium avium-M. intracellulare: activation of bactericidal activity by GM-CSF. Infect. Immun. 59:1991;2396-2402.
12. 3H-drihydrostreptomycin by macrophages in culture. Infect. Immun. 2:1970;89-95.
13. Ceresa R.J. Block and Graft Copolymerization. 1976;Wiley, NY.
14. Cornforth J.W., Hart P.D. Mycobacterium tuberculosis in macrophages: effect of certain surfactants and other membrane-active compounds. Science. 162:1968;686-689.
15. Denis M. Human monocytes/macrophages: NO or no NO. J. Leukocyte Biol. 55:1994;682-684.
16. Denis M., Gregg E. Recombinant tumour necrosis factor-alpha decreases whereas recombinant interleukin-6 increases growth of a virulent strain of Mycobacterium avium in human macrophages. Immunology. 71:1990;139-141.
17. Doherty T., Sher A. IL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. J. Immunol. 160:1998;5428-5435.
18. Doucet-Populaire F., Capobianco J., Zakula D., Jalier V., Goldman R. Molecular basis of clarithromycin activity against Mycobacterium avium and Mycobacterium smegmatis. J. Antimicrob. Chemother. 41:1998;179-187.
19. Frehel C., Offredo C., de Chastellier C. The phagosomal environment protects virulent Mycobacterium avium from killing and destruction by clarithromycin. Infect. Immun. 65:1997;2792-2802.
20. Hass R., Prudovsky I., Kruhoffer M. Differential effects of phorbol ester on signaling and gene expression in human leukemia cells. Leukemia Res. 21:1997;589-594.
21. Hoffner S.E., Svenson S.B. Studies on the role of the mycobacterial cell envelope in the multiple drug resistance of atypical mycobacteria. Res. Microbiol. 142:1991;448-451.
22. Honore N., Cole S.T. Streptomycin resistance in mycobacteria. Antimicrob. Agents Chemother. 38:1994;238-242.
23. Hunter R., Bennett B. The adjuvant activity of nonionic block polymer surfactants: II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers. J. Immunol. 133:1984;3167-3175.
24. Hunter R., Strickland F., Kezdy F. The adjuvant activity of nonionic block polymer surfactants: I. The role of hydrophile-lipophile balance. J. Immunol. 127:1981;1244-1250.
25. Hunter R.L., Bennett B. The adjuvant activity of nonionic block polymer surfactants: III. Characterization of selected biologically active surfaces. Scand. J. Immunol. 23:1986;287-300.
26. Hunter R.L., Jagannath C., Tinkley A., Behling C.A., Nolte F. Enhancement of antibiotic susceptibility and suppression of Mycobacterium avium complex growth by poloxamer 331. Antimicrob. Agents Chemother. 39:1995;435-439.
27. Jagannath C., Actor J.K., Hunter R.L. Induction of nitric oxide in human monocytes and monocyte cell lines by Mycobacterium tuberculosis. Nitric Oxide. 2:1998;174-186.
28. Jagannath C., Allaudeen H.S., Hunter R.L. Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo. Antimicrob. Agents Chemother. 39:1995;1349-1354.
29. Jagannath C., Allaudeen H.S., Hunter R.L.J., Emanuele R.M. Activity of CRL-1072 against Mycobacterium avium in vitro and in vivo. 35th Interscience Congress on Antimicrobial Agents and Chemotherapy. 1995;ASM, San Francisco.
30. Jagannath C., Emanuele M., Hunter R. The activity of poloxamer CRL1072 against Mycobacterium avium in macrophage culture and in mice. Antimicrob. Agents Chemother. 43:1999;2898-2903.
31. Jagannath C., Emanuele R.M., Hunter R.L. Activity of CRL-1072 against drug resistant strains of Mycobacterium tuberculosis in vitro and in vivo. Int. J. Antimicrob. Agents. 1999;. in press.
32. Jagannath C., Pai S., Actor J.K., Hunter R.L. CRL-1072 enhances antimycobacterial activity of human macrophages through interleukin-8. J. Interferon Cytokine Res. 19:1999;67-76.
33. Kiley S., Parker P. Defective microtubule reorganization in phorbol ester-resistant U937 variants: reconstitution of the normal cell phenotype with nocodazole treatment. Cell Growth Differ. 8:1997;231-242.
34. Koga H., Miyazaki Y., Kohno S., Hara K. A drug delivery system and biological response modifiers for the treatment of mycobacterial infection. Kekkaku. 69:1994;113-118.
35. Larrick J., Fischer D., Anderson S., Koren H. Characterization of a human macrophage-like cell line stimulated in vitro: a model of macrophage functions. J. Immunol. 125:1980;6-12.
36. Lundsted L.G., Schmolka I.R. The synthesis and properties of block copolymer polyol surfactants. Ceresa R.J. Block and Graft Copolymerization. 1976;1-103 Wiley, London.
37. Maurer N., Mori A., Palmer L., Monck M.A., Mok K.W., Mui B., Akhong Q.F., Cullis P.R. Lipid-based systems for the intracellular delivery of genetic drugs. Mol. Membr. Biol. 16:1999;129-140.
38. Naik S.P., Samsonoff W.A., Ruck R.E. Effects of surface-active agents on drug susceptibility levels and ultrastructure of Mycobacterium avium complex organisms isolated from AIDS patients. Diagn. Microbiol. Infect. Dis. 11:1988;11-19.
39. Newman G.W., Gan H.X., McCarthy P.L., Remold H.G. Survival of human macrophages infected with Mycobacterium avium intracellulare correlates with increased production of tumor necrosis factor-alpha and IL-6. J. Immunol. 147:1991;3942-3948.
40. Nikaido H. Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science. 264:1994;382-388.
41. Page B., Page M., Noel C. A fluorometric assay for cytotoxicity measurements in vitro. Int. J. Oncol. 3:1993;473-476.
42. Rastogi N., Frehel C., Ryter A., Ohayon H., Lesourd M., David H.L. Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for the exclusion of antimicrobial agents? Antimicrob. Agents Chemother. 20:1981;666-677.
43. Robinson R.F., Nahata M.C. A comparative review of conventional and lipid formulations of amphotericin B. J. Clin. Pharm. Ther. 24:1999;249-257.
44. Sellmayer A., Obermeier H., Weber C. Intrinsic cyclooxygenase activity is not required for monocytic differentiation of U937 cells. Cell Signal. 9:1997;91-96.
45. Shahan T.A., Siegel P.D., Sorenson W.G., Kushner W.G., Lewis D.M. A sensitive new assay for tumour necrosis factor. J. Immunol. Methods. 175:1994;181-187.
46. Shiratsuchi H., Johnson J., Ellner J. Bidirectional effects of cytokines on the growth of Mycobacterium avium within human monocytes. J. Immunol. 146:1991;3165-3170.
47. Siddiqi A., Jennings V.M., Kidd M.R., Actor J.K., Hunter R.L. Evaluation of electrochemiluminescence and bioluminescence based assays for quantitating specific DNA. J. Clin. Lab. Anal. 10:1996;423-431.
48. Stermitz F.R., Lorenz P., Tawara J.N., Zenewicz L.A., Lewis K. Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5′-methoxyhydnocarpin, a multidrug pump inhibitor [In Process Citation]. Proc. Natl. Acad. Sci. U. S. A. 97:2000;1433-1437.
49. Sturgill-Koszycki S., Schlesinger P., Chakraborty P., Haddix P., Collins H., Fok A., Allen R., Gluck S., Heuser J., Russell D. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science. 263:1994;678-681.
50. Svetic A., Finkleman F.D., Jain Y.C., Diefenbach C.W., Scott D.E., McCarthy K.F., Steinberg A.D., Gause W.C. Cytokine gene expression after in vivo primary immunization with goat antibody to mouse IgD antibody. J. Immunol. 147:1991;2391-2397.
51. Tepperman B.L., Soper B.D. Ca(2+)-mediated damage to rabbit gastric mucosal cells: modulation by nitric oxide. Eur. J. Pharmacol. 293:1995;259-266.
52. Vaara M. Agents that increase the permeability of the outer membrane. Microbiol. Rev. 56:1992;395-411.
53. Wynn T.A., Eltoum I., Cheever A.W., Lewis F.A., Gause W.C., Sher A. Analysis of cytokine mRNA expression during primary granuloma formation induced by eggs of Schistosoma mansoni. J. Immunol. 151(3):1993;1430-1440.
54. Yokoyama M. Block copolymers as drug carriers. Crit. Rev. Ther. Drug Carrier Syst. 9:1992;213-248.
55. Zimmerli S., Edwards S., Ernst J. Selective receptor blockade during phagocytosis does not alter the survival and growth of Mycobacterium tuberculosis in human macrophages. Am. J. Respir. Cell. Mol. Biol. 15:1996;760-770.